Lexeo CEO Sells $313K Stake as Company Releases Clinical Data and Executes Leadership Moves
Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend sold 55,000 shares on April 6, 2026, in a transaction totaling $313,137, according to an SEC Form 4. The sale, carried out under a Rule 10b5-1 plan adopted November 13, 2025, occurred as the company presented clinical data for AAV-based therapies LX2006 and LX2020 and announced senio…